 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Aura Biosciences Inc (AURA Research Report). The associated price t...

Aura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial Health

For the last three days, A.I.dvisor has detected that AURA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Aura Biosciences (AURA, $7.7) Aroon Indicator entered a Downtrend on March 27, 2024.

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer...

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Recap: Aura Biosciences Q4 Earnings

Aura Biosciences (NASDAQ:AURA  Get Free Report) and Atara Biotherapeutics (NASDAQ:ATRA  Get Free Report) are both small-cap medical companies, but which is the better investment? We...

Contrasting Aura Biosciences (NASDAQ:AURA) and Atara Biotherapeutics (NASDAQ:ATRA)

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced...

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences (AURA, $8) Aroon Indicator entered a Downtrend on February 13, 2024.

Investors considering a purchase of Aura Biosciences Inc (AURA) shares, but cautious about paying the going market price of 8.25/share, might benefit from considering selling puts among the...

Commit To Purchase Aura Biosciences At $7.50, Earn 32.6% Annualized Using Options

Aura Biosciences (AURA, $8.9) Aroon Indicator entered a Downtrend on February 12, 2024.

Aura Biosciences (AURA, $8.62) Aroon Indicator entered a Downtrend on February 09, 2024.

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Volume (M)	162,912.00
52-Wk High	$13.50
52-Wk Low	$5.99

AURA Aura Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals